Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Interdialytic peritoneal ultrafiltration with 10% dextrose solution: Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks

Study summary

Sodium accumulates in the tissues of patients with kidney disease and impairs survival. Three-times weekly, standard hemodialysis alone cannot remove excess sodium efficiently. A sample of 10 chronic hemodialysis patients will undergo a 5-week, pilot, interventional study to test the efficacy of additional sodium removal in-between hemodialysis sessions, twice per week, for three weeks. Tissue sodium removal will be achieved with peritoneal dialysis after the surgical insertion of a peritoneal dialysis catheter. Tissue sodium removal will be assessed at the beginning and at the end of the study with sodium magnetic resonance imaging of a peripheral limb (leg). Patients will also undergo monitoring for symptoms and blood pressure throughout the study to assess the safety of this procedure.

Eligibility

Primary outcome measure(s)

• Skin sodium concentration — End of week 4
  Skin sodium concentration at the end of week 4 as measured by sodium-23 magnetic resonance imaging of the leg.
• Adverse events — iPUF interventions on Week 2, 3 and 4
  Completion of the iPUF treatment without adverse events

Trial sites (1)

More London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials in Canada

Other trials for the same condition